Subscribe to RSS
DOI: 10.1055/s-2005-916254
Suppression of Collagen-Induced Arthritis by Oral Administration of the Citrus Flavonoid Hesperidin
Publication History
Received: October 5, 2005
Accepted: October 31, 2005
Publication Date:
10 February 2006 (online)
Abstract
The preventive and therapeutic effects of the Citrus flavonoid hesperidin (HES) on the development of collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis (RA), were investigated. Mice were administered orally HES three times a week starting from either the onset (day 21) of secondary immunization or on day 31, when the CIA development had reached a plateau. In both cases, treatment with HES resulted in a significant suppression of clinical scores and improvement of histological features. These results suggest that oral administration of HES could be effective for treating human RA patients.
References
- 1 Feldmann M, Brennan F M, Chantry D, Haworth C, Turner M, Katsikis P. et al . Cytokine assays: role in evaluation of the pathogenesis of autoimmunity. Immunol Rev. 1991; 119 105-23
- 2 Elson C J, Thompson S J, Westacott C I, Bhoola K D. Mediators of joint swelling and damage in rheumatoid arthritis and pristane induced arthritis. Autoimmunity. 1992; 13 327-31
- 3 Klareskog L, McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-α and the possible absence of specific immune reactions. Curr Opin Immunol. 1999; 11 657-62
- 4 Chu C Q, Field M, Feldmann M, Maini R N. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991; 34 1125-32
- 5 Brahn E, Peacock D J, Banquerigo M L, Liu D Y. Effects of tumor necrosis factor α (TNF-α) on collagen arthritis. Lymphokine Cytokine Res. 1992; 11 253-6
- 6 Mikuls T R, Weaver A L. Lessons learned in the use of tumor necrosis factor-α inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep. 2003; 5 270-7
- 7 Taylor P C. Anti-TNFα therapy for rheumatoid arthritis: an update. Intern Med. 2003; 42 15-20
- 8 Shanahan J C, St Clair W. Tumor necrosis factor-α blockade: a novel therapy for rheumatic disease. Clin Immunol. 2002; 103 231-42
- 9 Graninger W B, Smolen J S. One-year inhibition of tumor necrosis factor-α: a major success or a larger puzzle. Curr Opin Rheumatol. 2001; 13 209-13
- 10 Feldmann M, Maini R N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol. 2001; 19 163-96
- 11 Kawaguchi K, Kikuchi S, Hasegawa H, Maruyama H , Morita H, Kumazawa Y. Suppression of lipopolysaccharide-induced tumor necrosis factor-release and liver injury in mice by naringin. Eur J Pharmacol. 1999; 368 245-50
- 12 Kawaguchi K, Kikuchi S , Hasunuma R, Maruyama H , Yoshikawa T, Kumazawa Y. A citrus flavonoid hesperidin suppresses infection-induced endotoxin shock in mice. Biol Pharm Bull. 2004; 27 679-83
Dr. Professor Yoshio Kumazawa
Department of Biosciences
School of Science and Graduate School of Fundamental Life Science
Kitasato University
1-15-1 Kitasato
Sagamihara 228-8555
Japan
Phone: +81-42-778-9534
Fax: +81-42-778-9534
Email: kumazawa@sci.kitasato-u.ac.jp